Helen Diller Family Comprehensive Center, University of California, San Francisco, CA 94115, USA.
Future Oncol. 2018 Oct;14(24):2461-2469. doi: 10.2217/fon-2018-0178. Epub 2018 Jul 12.
Chemotherapy-induced alopecia remains an emotionally traumatic side effect for cancer patients that impacts the quality of life, may be protracted in duration and may influence treatment decisions. Scalp cooling has been shown to be effective in preventing chemotherapy-induced alopecia. The DigniCap Scalp Cooling System is designed to prevent hair loss by cooling the scalp to reduce the impact of chemotherapy on hair follicle cells. Recent studies have shown the safety, efficacy and low-grade toxicity of the DigniCap System with a 66.3% success rate in hair preservation (n = 106) relative to 0% in a nonrandomized control group according to a prospective pivotal study. Data also support improved quality of life in several domains. Two scalp cooling devices including the DigniCap are now US FDA cleared and can be offered as a part of standard of care.
化疗引起的脱发仍然是癌症患者情绪上的创伤性副作用,会影响生活质量,持续时间可能较长,并可能影响治疗决策。头皮冷却已被证明可有效预防化疗引起的脱发。DigniCap 头皮冷却系统旨在通过冷却头皮来防止脱发,从而降低化疗对毛囊细胞的影响。最近的研究表明,DigniCap 系统具有安全性、有效性和低级别毒性,根据前瞻性关键研究,相对于非随机对照组的 0%,其在保留头发方面的成功率为 66.3%(n=106)。数据还支持在多个领域改善生活质量。包括 DigniCap 在内的两种头皮冷却设备现已获得美国 FDA 批准,可作为标准护理的一部分提供。